Dr. Jacqueline Kraveka is an associate professor of pediatrics and a pediatric hematologist-oncologist at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. She was born in Velasco, Cuba and immigrated to the United States when she was 4 years of age. Dr. Kraveka received her undergraduate degree from Columbia University in 1989 and her medical degree from Nova Southeastern University College of Osteopathic Medicine in 1994. She completed her residency in pediatrics at Miami Children’s Hospital in 1997 and fellowship in pediatric hematology oncology at the Medical University of South Carolina in 2000. Since 2000, she has been on staff at the Medical University of South Carolina Children’s Hospital.
Dr. Kraveka’s clinical practice is focused on pediatric oncology. Her clinical interests include neuroblastoma, pediatric sarcomas, pediatric precision medicine, and clinical trial development. She is actively involved in clinical pediatric research in the Children’s Oncology Group (COG) and Beat Childhood Cancer (BCC) consortia and serves as the institutional principal investigator for these consortia and and as such, she is responsible for the conduct of over 50 Phase I, II, and III clinical trials for pediatric oncology patients at MUSC. Dr. Kraveka has been involved in the development of over 10 pediatric clinical trials for children with cancer. She serves on the COG Neuroblastoma and Diversity and Health Disparities Committees and is a member of the BCC Executive and Scientific Committees. Dr. Kraveka has been honored as a “Top Doctor” and "Exceptional Women in Medicine” by Castle Connolly. She was selected as a “Health Care Hero” by the Charleston Regional Business Journal.
Dr. Kraveka is also very involved in translational and bench research and has the only research laboratory in South Carolina dedicated to pediatric cancer. Dr. Kraveka’s current research focuses on sphingolipid and retinoid mediated therapies in pediatric cancers and the function and regulation of the enzyme dihydroceramide desaturase (DEGS-1) in pediatric cancer. The long-term goals of her research are to develop more effective treatments for children with cancer.